AI heart sound digital twin analytics market seen reaching $1.91 billion by 2030

The global market for AI heart sound digital twin analytics is projected to grow from $0.68 billion in 2025 to $1.91 billion by 2030, according to The Business Research Company. The report points to rising cardiovascular disease, demand for personalized medicine and wider use of AI in diagnostics as the main growth drivers.

Why it matters: - AI heart sound digital twin analytics could help clinicians detect cardiac problems earlier and monitor patients more continuously. - The market’s projected jump to $1.91 billion by 2030 signals stronger adoption of AI tools in cardiac diagnostics and care workflows.

What happened: - The Business Research Company released its Artificial Intelligence (AI) Heart Sound Digital Twin Analytics Global Market Report 2026. - The report projects the market will grow from $0.68 billion in 2025 to $0.84 billion in 2026. - The market is forecast to reach $1.91 billion by 2030. - The report estimates a 23.3% CAGR from 2025 to 2026 and a 23.0% CAGR through 2030. - North America held the largest market share in 2025.

The details: - AI heart sound digital twin analytics uses artificial intelligence to build a virtual simulation of a patient’s heart sound profile. - The technology analyzes heart sounds to replicate cardiac function, detect abnormalities and predict cardiovascular issues. - The market’s recent growth is tied to rising cardiovascular disease rates, digital auscultation advances, broader AI use in clinical diagnostics, remote patient monitoring and larger cardiac datasets. - The forecast period is supported by demand for early cardiac risk detection, personalized cardiology, cloud-based clinical analytics, continuous monitoring and deeper AI integration into clinical workflows. - The report says cardiovascular disease remains a major driver because conditions such as coronary heart disease, heart failure, stroke and hypertension remain widespread. - The report says unhealthy diets high in saturated fats, trans fats, added sugars and sodium contribute to blood pressure, obesity and elevated cholesterol. - The technology supports early diagnosis, personalized treatment planning and real-time cardiac monitoring. - The report cites the American College of Cardiology as saying cardiovascular disease remained the leading cause of disability-adjusted life years and deaths globally, with an estimated 437 million CVD DALYs in 2023. - Personalized medicine is another growth driver because AI heart sound digital twin analytics can create patient-specific heart models for more tailored cardiac care. - The report cites the Personalized Medicine Coalition as saying the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, up from 12 in 2022. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa as additional regional markets.

Between the lines: - The market forecast suggests AI is moving from experimental support tools toward more routine use in cardiology. - The combination of diagnostic pressure, chronic disease burden and personalized care demand is pushing healthcare systems toward software that can interpret patient-specific signals faster than traditional workflows. - North America’s lead likely reflects its stronger digital health infrastructure and faster adoption of advanced clinical analytics.

What's next: - The report expects continued market expansion as healthcare providers increase use of cloud analytics, continuous monitoring and AI-based diagnostic support. - Broader adoption will likely depend on how quickly clinical workflows absorb these tools and how well they prove value in real-world cardiac care. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated trend analysis.

The bottom line: - AI heart sound digital twin analytics is moving into a fast-growth phase, with rising heart disease rates and personalized medicine demand driving adoption across cardiac care.